| abstract |
The present invention is also known as a beta-site amyloid cleavage enzyme, BACE, in particular BACE1 and/or BACE2 (where BACE1 is also known as Asp2, or memapsin2 and BACE2 is also known as Asp1, memapsin 1 or DRAP). It relates to a novel 6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazin-6-yl derivative as an inhibitor of beta-secretase. The present invention also provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds and compositions, and disorders involving beta-secretase, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with lewy bodies, Down syndrome, stroke-associated dementia, Parkinson's disease-associated dementia, Alzheimer's type dementia, beta-amyloid-associated dementia, age-related macular degeneration, type 2 diabetes and other metabolic disorders. |